InteliCare Finalizes FY26 Capital Reconciliation, Files Overdue Appendix 3H for Expired Options

InteliCare’s Capital Structure as of 30 June 2026

Following the completion of its financial year reconciliation, InteliCare Holdings Limited disclosed a detailed breakdown of its issued capital. The primary security class consists of 714,754,276 ordinary fully paid shares. Additionally, the capital structure includes multiple classes and series of unlisted options and performance rights, reflecting various equity incentive arrangements established over time.

The unlisted options portfolio includes four series: ICROPT13 options exercisable at $0.05 per share expiring 30 May 2027 (7,000,000 options); ICROPT14 options exercisable at $0.02 per share expiring 30 August 2027 (112,249,999 options); ICROPT15 options exercisable at $0.02 per share expiring 15 December 2028 (20,000,000 options); and ICROPT16 options exercisable at $0.04 per share expiring 21 May 2029 (15,000,000 options). These series serve various corporate purposes including employee remuneration and equity incentives.

Complex Performance Rights Portfolio with Multiple Vesting and Expiry Dates

InteliCare’s performance rights structure is notably complex, encompassing 20 distinct classes and series designed to support diverse corporate objectives. The company disclosed performance rights ranging from the oldest classes ICRPR3 and ICRPR4, each with 575,000 units, to newer classes varying from 2,000,000 to 7,000,000 units per class.

The portfolio includes foundational classes ICRPRA through ICRPRH without specified exercise prices, alongside later series ICRPRI through ICRPRU with exercise prices between $0.03 and $0.07 per share and expiry dates from November 2028 to December 2030. Classes A through H total 31,300,000 units with expiry dates between February and September 2028. This diversified structure likely targets different employee groups, management levels, or strategic milestones.

Expired Options and Delayed ASX Notification

During its year-end reconciliation, InteliCare identified that several historical unlisted options had expired per their contractual terms without the required ASX notifications being lodged. None of these options were exercised before expiry, resulting in their lapse and removal from the register. The company attributes the failure to lodge Appendix 3H forms at the time as inadvertent.

Upon discovery, InteliCare promptly prepared and lodged the outstanding Appendix 3H documents concurrently with this update. The company has committed to ensuring timely future notifications and confirms it remains compliant with ASX Listing Rules.

InteliCare’s AI-Powered Platform and Focus on Aged Care Market

InteliCare is an Australian technology company focused on predictive analytics hardware and software tailored for aged care and health sectors. Its proprietary Internet of Things (IoT) platform integrates smart sensors with AI to provide both B2B and B2C solutions, enabling individuals to age in place while supporting healthcare providers in delivering higher quality and more efficient services.

Headquartered at Level 1, 299 Vincent Street, Leederville, Western Australia, 6001, InteliCare’s mission emphasizes dignified ageing for Australians, leveraging technology to enhance aged care delivery. The company’s dual-market strategy targets institutional providers and individual consumers, positioning it to capture value amid growing demand for aged care services across Australia.

Governance and Administrative Controls Post-Reconciliation

The delayed Appendix 3H filings highlight aspects of InteliCare’s internal securities governance. While the year-end reconciliation process proved effective in identifying the notification lapse, the delay raises questions about ongoing administrative controls. The company has now rectified the issue and reaffirmed compliance with ASX Listing Rules.

InteliCare’s commitment to timely future lodgements signals improved administrative discipline. Although the delayed filings represent a technical breach of ASX procedures, no improper securities issuance occurred. The company’s prompt remediation through concurrent Appendix 3H lodgement and disclosure reflects its approach to resolving administrative matters.

Capital Management and Equity-Based Remuneration

The extensive unlisted options and performance rights indicate InteliCare’s reliance on equity incentives within its compensation framework. The four unlisted options series differ in exercise prices and expiry dates, likely corresponding to grants for various employee groups or management levels. The largest series, ICROPT16, comprises 15,000,000 options exercisable at $0.04 per share expiring 21 May 2029.

The 20 performance rights classes further illustrate layered incentive schemes aligned with company performance and strategic goals. Exercise prices range from $0.02 to $0.07 per share with staggered expiries, designed to motivate specific outcomes across organizational tiers. These instruments represent potential dilution to shareholders depending on future share price performance.

Shareholder Dilution and Capital Raising Considerations

The outstanding unlisted options total 154,249,999 units across four series, alongside substantial performance rights, pose significant potential dilution relative to the 714,754,276 ordinary shares on issue. If all in-the-money options and rights vest and are exercised, the equity structure would shift materially.

Investors should monitor vesting and exercise activity, as well as any future equity issuances. The staggered expiries suggest dilution will occur incrementally over coming years, potentially impacting share price at various intervals. InteliCare’s commitment to accurate, timely disclosure will enhance transparency regarding these securities’ exercise status.

Australian Aged Care Technology Sector Context

InteliCare operates within Australia’s aged care sector, which has faced heightened regulatory scrutiny and operational challenges, especially following the 2021 Royal Commission into Aged Care Quality and Safety. Demand for technology solutions that improve care quality and efficiency is increasing as providers respond to regulatory and consumer pressures.

The sector is shaped by an ageing population, rising service demand, and workforce constraints. AI and IoT technologies facilitating efficient service delivery, early health issue detection, and ageing in place align with these industry priorities. InteliCare’s positioning targets a growing market subject to evolving regulations and government funding policies.

Upcoming Milestones and Investor Watchpoints

Having completed its issued capital reconciliation and resolved the delayed option expiry notifications, InteliCare’s next key event will be the release of its full-year financial results for FY26. This report, expected to be lodged with the ASX per reporting obligations, will provide insights into financial performance, progress in commercialising its aged care technology, and management’s outlook.

Investors should also track announcements related to the exercise or vesting of unlisted options and performance rights, especially as series like ICROPT13 approach expiry in May 2027. Updates on capital raises, strategic partnerships, or significant customer wins within the aged care market will also be critical to assessing the company’s commercial trajectory and the value of outstanding equity incentives.